stock downgrade
William Blair Downgrades Lucira Health to Market Perform
As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022.
Roche to Acquire GenMark Diagnostics for $1.8B
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
Oppenheimer Downgrades Invitae to Perform Rating
Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares."
Evercore ISI Downgrades Twist Bioscience to In-Line Rating
The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear.
BTIG Downgrades Fulgent Genetics from Buy to Neutral
The investment bank said it expects demand for Fulgent's COVID-19 testing to decline over the next two years.
Oct 14, 2020
JP Morgan Rates Invitae Neutral
Oct 9, 2019
Waters Stock Downgraded by Barclays
Jul 16, 2019
Qiagen Stock Downgraded to 'In Line' by Evercore ISI
Jul 9, 2019
Cowen Downgrades Myriad Genetics' Stock
Dec 13, 2017
JP Morgan Downgrades Genomic Health to Underweight
Apr 19, 2017
Cantor Fitzgerald Downgrades PerkinElmer to Neutral
Jan 4, 2017